. Author manuscript; available in PMC: 2012 Jun 1.

Published in final edited form as: Cytotherapy. 2010 Aug 24;12(8):1056–1062. doi: 10.3109/14653249.2010.506506

Table I.

Patient characteristics and AML blast counts in NOD/SCID bone marrow. Two AML patient samples (UPN1 and UPN2) were used in the six sets of experiments. CTL (PR1, PR2 or pp65) were elicited from the same healthy donor in each set of experiments summarized. The percentage of blast counts in the bone marrow and the number of CD8⁺ CTL co-infused (in parentheses) are shown.

	Blast count in mouse bone marrow post-transfer (%) and number of CD8⁺ CTL infused

Patient characteristics	Experiment	PR1-CTL	PR2-CTL	pp65-CTL	AML
UPN1	1	18 (7 × 10⁵)	71 (4 × 10⁵)	ND	88
AML-M5, refractory disease	2	13 (4 × 10⁵)	ND	ND	74
64% blasts	3	11 (5 × 10⁵)	ND	ND	74
UPN2	1	10 (3 × 10⁵)	ND	56 (6 × 10⁵)	85
AML-M2, refractory relapse disease	2	4 (5 × 10⁵)	ND	54 (7 × 10⁵)	84
98% blasts	3	3 (7 × 10⁵)	ND	ND	72

ND, no data.